Sign In
Buy HSDT
$1.51
-0.120 (-7.36%)
At Close: Jun 23, 2026
Helius Announces First Portable Neuromodulation Stimulator (PoNS®) System Sale to the Veterans Affairs (VA) Healthcare System
07:00am, Monday, 23'rd Dec 2024
Initial order placed with Company's distributor at contracted price and represents operational implementation through VA Federal Supply Schedule (FSS) Contract Initial order placed with Company's dist
NEWTOWN, Pa., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuro
Helius Medical Technologies, Inc. to Present at the 2024 ThinkEquity Conference
08:00am, Friday, 18'th Oct 2024
NEWTOWN, Pa., Oct. 18, 2024 – PRISM MediaWire – Helius Medical Technologies, Inc.
Helius Medical Technologies, Inc. to Present at the 2024 ThinkEquity Conference
08:00am, Friday, 18'th Oct 2024
NEWTOWN, Pa., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (“Helius” or the “Company”) [Nasdaq: HSDT], a neurotech company focused on delivering a novel therapeutic neur
-- Reimbursement Determination for the PoNS Mouthpiece (HCPCS code A4594) set at $2,963.30 on Lump Sum Payment to be challenged by Helius -- -- National Reimbursement Payment Determination from CMS fo
Helius Medical Technologies, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
05:00pm, Friday, 16'th Aug 2024
NEWTOWN, Pa., Aug. 16, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq: HSDT) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announ
Helius Medical Technologies, Inc. (HSDT) Q2 2024 Earnings Call Transcript
09:33pm, Monday, 12'th Aug 2024
Helius Medical Technologies, Inc. (NASDAQ:HSDT ) Q2 2024 Results Conference Call August 12, 2024 4:30 PM ET Company Participants Michelle Bilski - IR Dane Andreeff - President and CO Jeff Mathiesen -
Helius Medical Technologies, Inc. Reports Second Quarter 2024 Financial Results
04:05pm, Monday, 12'th Aug 2024
NEWTOWN, Pa., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuro
Helius Medical Technologies, Inc. to Release Second Quarter 2024 Financial Results on August 12, 2024
04:36pm, Tuesday, 06'th Aug 2024
NEWTOWN, Pa., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ: HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neur
Helius Medical Technologies, Inc. Completes Site Participation Enrollment for its U.S. Registrational Program in Stroke
07:00am, Monday, 17'th Jun 2024
-- Inclusion of the top neurorehabilitation centers REHABOLOGYM, Neurology Center of New England, and MGH Institute of Health Professions completes site participation enrollment for the U.S. registrat
Helius Medical Technologies, Inc. to Present at the Spring MicroCap Rodeo Conference
12:30pm, Friday, 31'st May 2024
NEWTOWN, PA / ACCESSWIRE / May 31, 2024 / Helius Medical Technologies, Inc., (Nasdaq:HSDT) ("Helius" or the "Company"), a neurotech company focused on delivering a novel therapeutic neuromodulation ap
Company Will Highlight Major Milestones on Accessibility and Reimbursement Fronts Company Will Highlight Major Milestones on Accessibility and Reimbursement Fronts
-- Approval provides U.S. veterans and other U.S. government agency employees who suffer gait and balance impairment due to multiple sclerosis (MS) access to the only portable neurostimulation therapy
Helius Medical Technologies, Inc. (HSDT) Q1 2024 Earnings Call Transcript
07:21pm, Monday, 13'th May 2024
Helius Medical Technologies, Inc. (NASDAQ:HSDT ) Q1 2024 Results Conference Call May 13, 2024 4:30 PM ET Company Participants Michelle Bilski - Investor Relations-In-Site Communications Dane Andreeff
Helius Medical Technologies, Inc. Reports First Quarter 2024 Financial Results
04:05pm, Monday, 13'th May 2024
NEWTOWN, Pa., May 13, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neurom
